Pharvaris (NASDAQ:PHVS – Get Rating) traded down 9.1% during trading on Tuesday . The stock traded as low as $23.57 and last traded at $24.99. 34 shares changed hands during mid-day trading, a decline of 100% from the average session volume of 33,872 shares. The stock had previously closed at $27.50.
PHVS has been the subject of a number of recent research reports. JMP Securities initiated coverage on Pharvaris in a research note on Wednesday, May 25th. They set an “outperform” rating and a $34.00 price target for the company. SVB Leerink dropped their price target on Pharvaris from $50.00 to $45.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 30th. Finally, Morgan Stanley decreased their price target on Pharvaris to $40.00 and set an “overweight” rating for the company in a research note on Tuesday, May 17th.
The stock has a 50-day simple moving average of $18.34 and a 200 day simple moving average of $17.58. The company has a market cap of $796.64 million, a PE ratio of -9.61 and a beta of -0.44.
Several large investors have recently added to or reduced their stakes in the company. Suvretta Capital Management LLC purchased a new stake in shares of Pharvaris in the 4th quarter valued at about $11,908,000. Novo Holdings A S lifted its holdings in shares of Pharvaris by 23.2% in the 4th quarter. Novo Holdings A S now owns 516,321 shares of the company’s stock valued at $7,430,000 after purchasing an additional 97,378 shares during the last quarter. Eventide Asset Management LLC lifted its holdings in shares of Pharvaris by 23.6% in the 1st quarter. Eventide Asset Management LLC now owns 302,619 shares of the company’s stock valued at $5,659,000 after purchasing an additional 57,694 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Pharvaris by 90.6% in the 4th quarter. Goldman Sachs Group Inc. now owns 57,516 shares of the company’s stock valued at $828,000 after purchasing an additional 27,342 shares during the last quarter. Finally, Viking Global Investors LP lifted its holdings in shares of Pharvaris by 1.0% in the 1st quarter. Viking Global Investors LP now owns 2,480,319 shares of the company’s stock valued at $46,382,000 after purchasing an additional 24,783 shares during the last quarter. 79.32% of the stock is owned by institutional investors and hedge funds.
About Pharvaris (NASDAQ:PHVS)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE).
- Get a free copy of the StockNews.com research report on Pharvaris (PHVS)
- Should Silver Stocks Be A Part Of Your Portfolio?
- ABM Industries, A Clean Play For Dirty Economic Times
- This Still Isn’t A Buyable Bottom For Stocks
- Two Defensive Stocks To Get Aggressive With
- Dividend-Paying Midstream Oil Companies That Could Help You The Mitigate Market Volatility
Receive News & Ratings for Pharvaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharvaris and related companies with MarketBeat.com's FREE daily email newsletter.